Back to Search Start Over

Development and validation of a Behçet's Disease Damage Index for adults with BD: An Explicit, Composite and Rated (ECR) tool.

Authors :
Gheita TA
Hammam N
Fawzy SM
Abd El-Latif E
El-Gazzar II
Samy N
El-Hammady DH
Abdel Noor R
El-Shebini E
El-Najjar AR
Eesa NN
Salem MN
Ibrahim SE
El-Essawi DF
Elsaman AM
Senara S
Fathi HM
Sallam RA
El Shereef RR
Abd Elazeem MI
Fawzy RM
Khalil NM
Shahin D
El-Saadany HM
ElKhalifa M
Nasef SI
Abdalla AM
Noshy N
Said EA
Saad E
Moshrif AH
El-Shanawany AT
Abdel-Fattah YH
Raafat HA
Khalil HM
Source :
International journal of rheumatic diseases [Int J Rheum Dis] 2021 Aug; Vol. 24 (8), pp. 1071-1079. Date of Electronic Publication: 2021 Jul 19.
Publication Year :
2021

Abstract

Background: Behçet's disease (BD) is a chronic multisystem variable vessel vasculitis. Disease damage is irreversible and permanent. Validated tools evaluating damage are limited. Enhancements in the clinical treatment of vasculitis will take place from the development of refined and exclusive indices for individual vasculitic syndromes including BD and attempting their international validation.<br />Objectives: This aim was to develop and validate a simple BD Damage Index (BDI).<br />Methods: This was a nationwide study including 1252 BD patients. The work consisted of 3 stages. Stage 1: items generation for score content. Stage 2: items selection for the draft score was performed by an expert rheumatologist. Stage 3: the content validity of the draft score was assessed and BDI, Vasculitis Damage Index (VDI), Antineutrophil cytoplasmic antibody-associated Vasculitis Index of Damage (AVID) and Combined Damage Assessment Index (CDAI) were calculated and compared.<br />Results: The mean age of the BD patients was 36.1 ± 9.9 years. Stages 1 and 2 resulted in a BDI instrument containing 73 items with a maximum score of 100. Stage 3, the VDI, CDAI, AVID, and BDI were 2.9 ± 2.2, 3.1 ± 2.3, 3.1 ± 2.3 and 5.1 ± 2.9, respectively. High correlations (r = .9) between comparable damage scores assured acceptable concurrent validity.<br />Conclusion: The proposed BDI represents a new robust and potentially useful tool when dealing with BD chronic status.<br /> (© 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.)

Details

Language :
English
ISSN :
1756-185X
Volume :
24
Issue :
8
Database :
MEDLINE
Journal :
International journal of rheumatic diseases
Publication Type :
Academic Journal
Accession number :
34288457
Full Text :
https://doi.org/10.1111/1756-185X.14166